Clinical Trial Update: Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant pembrolizumab in vulvar squamous cell carcinoma as a proof-of-concept study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvar Cancer
• Vulvar Neoplasm
• Vulvar Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Vulva Cancer, Vulva Neoplasm | Phase 2 | Status: UNKNOWN